NASDAQ:PSNL

Personalis Stock News

Healthcare > Medical - Diagnostics & Research

Buy PSNL

*Your capital is at risk

$10.78

-0.360 (-3.23%)

At Close: Jun 03, 2026

Personalis Reports Third Quarter 2025 Financial Results

04:01pm, Tuesday, 04'th Nov 2025

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2025

Personalis to Announce Third Quarter 2025 Financial Results

04:01pm, Tuesday, 21'st Oct 2025

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2025 financial results o

Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last?

04:16am, Friday, 17'th Oct 2025

Personalis (PSNL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

09:00am, Thursday, 16'th Oct 2025

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (L

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05:35pm, Monday, 15'th Sep 2025

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors grant

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

04:05pm, Wednesday, 10'th Sep 2025

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced its collaboration with a leading breast cancer team from Yale C

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

04:05pm, Wednesday, 03'rd Sep 2025

Personalis to Participate in Upcoming Investor Conferences

04:01pm, Wednesday, 27'th Aug 2025

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the following confer

Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL)

10:36am, Wednesday, 13'th Aug 2025

The heavy selling pressure might have exhausted for Personalis (PSNL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts

After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL)

10:35am, Tuesday, 12'th Aug 2025

Personalis (PSNL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisin

All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy

01:01pm, Friday, 08'th Aug 2025

Personalis (PSNL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

08:11am, Wednesday, 06'th Aug 2025

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Wednesday.

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by